Recap: Exact Sciences Q4 Earnings
Shares of Exact Sciences (NASDAQ:EXAS) fell in after-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 59.46% over the past year to ($0.15), which beat the estimate of ($0.22).
Revenue of $466,339,000 higher by 57.77% year over year, which beat the estimate of $446,220,000.
Looking Ahead
Exact Sciences Q4 Adj EPS $(0.15) Beats $(0.22) Est., Sales $466.30M Beat $446.22M Estimate
Details Of The Call
Date: Feb 16, 2021
Time: 05:00 PM
Recent Stock Performance
Company's 52-week high was at $159.54
52-week low: $35.25
Price action over last quarter: Up 14.49%
Company Overview
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in liquid biopsy (blood-based) cancer screening.
Posted-In: BZI-RecapsEarnings
